IP Library Granted Patent US 8,383,820
Granted Patent B2
US 8,383,820 · App. 12/528,229 · Granted Feb 26, 2013

N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,820
App. No.
12/528,229
Granted
Feb 26, 2013
Kind
B2
Abstract

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

Claims (52)

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

R 1 is hydrogen;

R 2 is 5-hydroxy-adamantan-2-yl;

R 4 is hydrogen;

R 5 is hydrogen; and

Y is selected from the group consisting of 2-[1-(carboxylic acid isopropylamide)-piperidin-4-yl]-ethoxy, 6-chloro-pyridin-3-ylmethoxy, tetrahydropyran-4-yl-methoxy, 2-(2-oxo-pyrrolidin-1-yl)-ethoxy, 5-chloro-pyridin-2-yloxy, 6-bromo-pyridin-3-yloxy, phenethyloxy, 2-(tetrahydropyran-4-yl)-ethoxy, benzyloxy, 2-(1-cyclopropane-sulfonyl-piperidin-4-yl)-ethoxy, and 4-fluorobenzyloxy.

2. 4-{2-[3-(5-Hydroxy-adamantan-2-ylcarbamoyl)-phenoxy]-ethyl}-piperidine-1-carboxylic acid isopropylamide, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , where the compound is 4-{2-[3-(5-hydroxy-adamantan-2-ylcarbamoyl)-phenoxy]-ethyl}-piperidine-1-carboxylic acid isopropylamide.

4. 3-(6-Chloro-pyridin-3-ylmethoxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , where the compound is 3-(6-chloro-pyridin-3-ylmethoxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide.

6. N-(5-Hydroxy-adamantan-2-yl)-3-(tetrahydro-pyran-4-ylmethoxy)-benzamide, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 , where the compound is N-(5-hydroxy-adamantan-2-yl)-3-(tetrahydro-pyran-4-ylmethoxy)-benzamide.

8. N-(5-Hydroxy-adamantan-2-yl)-3-[2(2-oxo-pyrrolidin-1-yl)-ethoxy]-benzamide, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8 , where the compound is N-(5-hydroxy-adamantan-2-yl)-3-[2-(2-oxo-pyrrolidin-1-yl)-ethoxy]-benzamide.

10. 3-(5-Chloro-pyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10 , where the compound is 3-(5-chloro-pyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide.

12. 3-(6-Bromo-pyridin-3-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, or a pharmaceutically acceptable salt thereof.

13. The compound of claim 12 , where the compound is 3-(6-bromo-pyridin-3-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide.

14. N-(5-Hydroxy-adamantan-2-yl)-3-phenethyloxy-benzamide, or a pharmaceutically acceptable salt thereof.

15. The compound of claim 14 , where the compound is N-(5-hydroxy-adamantan-2-yl)-3-phenethyloxy-benzamide.

16. N-(5-Hydroxy-adamantan-2-yl)-3-[2-(tetrahydro-pyran-4-yl)-ethoxy]-benzamide, or a pharmaceutically acceptable salt thereof.

17. The compound of claim 16 , where the compound is N-(5-hydroxy-adamantan-2-yl)-3-[2-(tetrahydro-pyran-4-yl)-ethoxy]-benzamide.

18. 3-Benzyloxy-N-(5-hydroxy-adamantan-2-yl)-benzamide, or a pharmaceutically acceptable salt thereof.

19. The compound of claim 18 , where the compound is 3-benzyloxy-N-(5- hydroxy-adamantan-2-yl)-benzamide.

20. 3-[2-(1-Cyclopropane-sulfonyl-piperidin-4-yl)-ethoxy]-N-(5-hydroxy-adamantan-2-yl)-benzamide, or a pharmaceutically acceptable salt thereof.

21. The compound of claim 20 , where the compound is 3-[2(1-cyclopropane-sulfonyl-piperidin-4-yl)-ethoxy]-N-(5-hydroxy-adamantan-2-yl)-benzamide.

22. 3-(4-Fluoro-benzyloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, or a pharmaceutically acceptable salt thereof.

23. The compound of claim 22 , where the compound is 3-(4-fluoro-benzyloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide.

24. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

25. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or excipient.

26. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier or excipient.

27. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier or excipient.

28. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier or excipient.

29. A pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier or excipient.

30. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier or excipient.

31. A pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier or excipient.

32. A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier or excipient.

33. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier or excipient.

34. A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier or excipient.

35. A pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable carrier or excipient.

36. A pharmaceutical composition comprising a compound of claim 13 and a pharmaceutically acceptable carrier or excipient.

37. A pharmaceutical composition comprising a compound of claim 14 and a pharmaceutically acceptable carrier or excipient.

38. A pharmaceutical composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier or excipient.

39. A pharmaceutical composition comprising a compound of claim 16 and a pharmaceutically acceptable carrier or excipient.

40. A pharmaceutical composition comprising a compound of claim 17 and a pharmaceutically acceptable carrier or excipient.

41. A pharmaceutical composition comprising a compound of claim 18 and a pharmaceutically acceptable carrier or excipient.

42. A pharmaceutical composition comprising a compound of claim 19 and a pharmaceutically acceptable carrier or excipient.

43. A pharmaceutical composition comprising a compound of claim 20 and a pharmaceutically acceptable carrier or excipient.

44. A pharmaceutical composition comprising a compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

45. A pharmaceutical composition comprising a compound of claim 22 and a pharmaceutically acceptable carrier or excipient.

46. A pharmaceutical composition comprising a compound of claim 23 and a pharmaceutically acceptable carrier or excipient.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Jan 27, 2021
From: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
To: VTV THERAPEUTICS LLC
Reel/Frame 055133/0214 →
SECURITY INTEREST Recorded Apr 18, 2018
From: VTV THERAPEUTICS LLC
To: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
Reel/Frame 045969/0774 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036254 FRAME: 0792. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 24, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS II LLC
Reel/Frame 036675/0399 →
RELEASE OF SECURITY INTEREST Recorded Aug 3, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS I LLC
Reel/Frame 036254/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: VTVX HOLDINGS II LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036242/0362 →
CHANGE OF NAME Recorded Jul 30, 2015
From: HIGH POINT PHARMACEUTICALS, LLC
To: VTVX HOLDINGS II LLC
Reel/Frame 036236/0159 →
SECURITY INTEREST Recorded Feb 26, 2015
From: HIGH POINT PHARMACEUTICALS, LLC
To: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
Reel/Frame 035103/0029 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0793 Recorded Apr 7, 2014
From: M&F TTP HOLDINGS LLC
To: HIGH POINT PHARMACEUTICALS, LLC
Reel/Frame 032621/0867 →
SECURITY AGREEMENT Recorded Aug 9, 2013
From: HIGH POINT PHARMACEUTICALS, LLC
To: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDINGS INC.
Reel/Frame 030982/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2009
From: EBDRUP, SOREN
To: HIGH POINT PHARMACEUTICALS, LLC
Reel/Frame 023325/0920 →